Literature DB >> 6895040

Comparison of different methods for decision-making in bioequivalence assessment.

D Mandallaz, J Mau.   

Abstract

If the regulatory requirements are symmetrical, the use of symmetrical confidence intervals as a decision rule for bioequivalence assessment leads, as shown by simulations, to better level properties and an inferior power compared to a rule based on shortest confidence intervals. A choice between these two approaches will have to depend on a loss function. For asymmetric regulatory requirements, symmetrical confidence intervals should not be used; however, a decision can still be based on posterior probabilities, pr (theta epsilon [r1, r2]/x), or shortest confidence intervals. For purposes of inference, presentation and interpretation of results, we think that the use of symmetrical confidence intervals alone can be misleading and we therefore recommend that the posterior probabilities and densities, or at least the shortest confidence intervals, be given.

Mesh:

Year:  1981        PMID: 6895040

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  13 in total

1.  Evaluation of bioequivalence studies.

Authors:  A P Grieve
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Spline functions in convolutional modeling of verapamil bioavailability and bioequivalence. II: study in healthy volunteers.

Authors:  J Popović; R Mitić; A Sabo; M Mikov; V Jakovljević; K Daković-Svajcer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2006 Apr-Jun       Impact factor: 2.441

Review 3.  Bioequivalence; its history, practice, and future.

Authors:  Kamal K Midha; Gordon McKay
Journal:  AAPS J       Date:  2009-10-06       Impact factor: 4.009

Review 4.  Review of methods and criteria for the evaluation of bioequivalence studies.

Authors:  G Pabst; H Jaeger
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

5.  A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability.

Authors:  D J Schuirmann
Journal:  J Pharmacokinet Biopharm       Date:  1987-12

6.  Interaction between furosemide and the converting enzyme inhibitor benazepril in healthy volunteers.

Authors:  I De Lepeleire; A Van Hecken; R Verbesselt; G Kaiser; A Barner; I Holmes; P J De Schepper
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

7.  Generalization of distribution--free confidence intervals for bioavailability ratios.

Authors:  V W Steinijans; E Diletti
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

8.  Group sequential extensions of a standard bioequivalence testing procedure.

Authors:  A L Gould
Journal:  J Pharmacokinet Biopharm       Date:  1995-02

9.  An exact confidence interval from untransformed data for the ratio of two formulation means.

Authors:  C S Locke
Journal:  J Pharmacokinet Biopharm       Date:  1984-12

10.  A new statistical procedure for testing equivalence in two-group comparative bioavailability trials.

Authors:  W W Hauck; S Anderson
Journal:  J Pharmacokinet Biopharm       Date:  1984-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.